logo
The Climate Solution Hiding In Plain Sight

The Climate Solution Hiding In Plain Sight

Forbes08-06-2025
We're drowning in climate headlines. Every week brings more reports about disappearing species, collapsing ecosystems, or yet another environmental tipping point. It's exhausting. And it's easy to feel like the damage is too big, too complex, or too far gone to fix.
That's what makes Ocean with David Attenborough—the new documentary directed by Toby Nowlan and narrated by Sir David Attenborough—so powerful. It doesn't offer false comfort or vague inspiration. It presents a clear, science-backed message: the ocean is more resilient than we thought, and protecting it is the most powerful thing we can do right now to restore the health of the planet.
Dr. Enric Sala has spent the last 15 years proving that point. Once a university professor, Sala left academia after realizing he was spending his days documenting the slow death of the sea. He now leads National Geographic's Pristine Seas initiative, which combines exploration, policy, science, and storytelling to create marine protected areas (MPAs) around the world. So far, his team has helped establish 29 of them—covering an area larger than the Amazon rainforest.
The findings so far are staggering. Fully protected marine reserves quickly regenerate. Fish populations can increase fivefold. Coral reefs damaged by bleaching events often recover in a few short years—if given the chance.
I first met Dr. Sala and saw him speak in 2019 at the National Geographic Explorers Festival in Washington DC. I had a chance to sit down recently with Sala and Nowlan, to talk about this documentary and what they hope the audience will take away from watching it.
'The resilience is extraordinary,' Sala told me. 'Everywhere where there is fishing and you create a [marine protected] area, marine life comes back. That's universal.'
These aren't isolated pockets of recovery. From the Southern Line Islands to the coasts of California, the pattern is the same: when you stop taking, the ocean gives back.
A bait ball in the open ocean near Azores.
Silverback Films and Open Planet Studios/Doug Anderson
Despite these results, just 3% of the global ocean is fully protected today. Scientists say we need to protect at least 30%—both land and sea—by 2030 to maintain a livable planet. That 30x30 goal has been endorsed by governments, conservationists, and NGOs around the world.
But Ocean isn't a policy documentary. It's not filled with charts and legislative jargon. It uses stunning visuals and emotional storytelling to make the science real—and personal.
The film's message is direct: saving the ocean isn't just a climate issue. It's a life support issue. Half of the oxygen we breathe comes from the sea. The ocean regulates temperature, absorbs carbon, and feeds billions. If it collapses, it will have a cascading effect that collapses everything else with it.
One thing that makes Ocean different from other environmental films is its focus on a single, proven action. While many documentaries leave viewers overwhelmed with advice—buy local, drive less, eat plant-based—Ocean makes a case for one big move: expand marine protection.
'We wanted to focus on one solution,' Sala explained. 'There is one proven solution that works everywhere… that actually can be applied by governments, by communities, by anybody.'
That simplicity is what gives the film power. It shows that this isn't just about global policies or top-down mandates. Coastal communities can start small, protecting local waters. Governments can scale efforts. Even viewers far from the sea can raise awareness and support legislation to help the cause.
The film is also shaped by director Toby Nowlan, whose credits include Planet Earth II and Our Planet. Nowlan has spent two decades filming the rarest, most vulnerable wildlife on Earth—including securing the best footage ever captured of the critically endangered Javan rhino.
With Ocean, he wanted to make one message stick: protecting the sea works. It's not theory. It's happening now.
That's why having Attenborough narrate the film matters. His voice has become a universal symbol of trust in nature storytelling. His presence here elevates the message, giving it weight at a time when public trust is rare and essential.
One of the moments that stuck with me most in our conversation was Sala's reminder that this isn't just about the Arctic or the Great Barrier Reef.
'If you live on the coast, you can be the person who leads your community to protect your ocean backyard,' he said.
That line matters. It reframes the ocean as not just a remote wilderness, but a shared resource that touches every life—no matter where we live.
We don't need another film telling us how bad things are. We need stories that show us how to fix it. Ocean with David Attenborough does exactly that.
It's beautiful, emotional, and urgent—but also deeply practical. The science is real. The path is clear. And the results are already visible in every corner of the sea that's been given time to heal.
If governments follow through on the 30x30 promise—and if communities join the push—we could see the greatest comeback story the natural world has ever told.
And it starts with protecting what's below the surface.
Check out Ocean with David Attenborough for yourself. It is available now to stream on Disney+ and Hulu.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Yahoo

time15 minutes ago

  • Yahoo

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

A UFC fight at the White House? Dana White says it's happening
A UFC fight at the White House? Dana White says it's happening

CNN

time16 minutes ago

  • CNN

A UFC fight at the White House? Dana White says it's happening

Media Donald TrumpFacebookTweetLink Follow Hours after Paramount and UFC announced a billion-dollar rights deal, Dana White said he had yet to hear from his friend, President Donald Trump, on his thoughts about the fight company's new streaming home. That was fine with White. The UFC CEO was set to travel to Washington on August 28 to meet with Trump and his daughter, Ivanka, to catch up and discuss logistics on the proposed Fourth of July fight card next year at the White House. Trump said last month he wanted to stage a UFC match on the White House grounds with upwards of 20,000 spectators to celebrate 250 years of American independence. 'It's absolutely going to happen,' White told The Associated Press. 'Think about that, the 250th birthday of the United States of America, the UFC will be on the White House south lawn live on CBS.' The idea of cage fights at the White House would have seemed improbable when the Fertitta brothers purchased UFC for $2 million in 2001 and put White in charge of the fledging fight promotion. White helped steer the company into a $4 billion sale in 2016 and broadcast rights deals with Fox and ESPN before landing owner TKO Group's richest one yet — a seven-year deal with Paramount starting in 2026 worth an average of $1.1 billion a year, with all cards on its streaming platform Paramount+ and select numbered events also set to simulcast on CBS. ESPN, Amazon and Netflix and other traditional sports broadcast players seemed more in play for UFC rights — White had previously hinted fights could air across different platforms — but Paramount was a serious contender from the start of the negotiating window. The Paramount and UFC deal came just days after Skydance and Paramount officially closed their $8 billion merger — kicking off the reign of a new entertainment giant after a contentious endeavor to get the transaction over the finish line. White said he was impressed with the vision Skydance CEO David Ellison had for the the global MMA leader early in contract talks and how those plans should blossom now that Ellison is chairman and CEO of Paramount. 'When you talk about Paramount, you talk about David Ellison, they're brilliant businessmen, very aggressive, risk takers,' White said. 'They're right up my alley. These are the kind of guys that I like to be in business with.' The $1.1 billion deals marks a notable jump from the roughly $550 million that ESPN paid each year for UFC coverage today. But UFC's new home on Paramount will simplify offerings for fans — with all content set to be available on Paramount+ (which currently costs between $7.99 and $12.99 a month), rather than various pay-per-view fees. Paramount also said it intends to explore UFC rights outside the US 'as they become available in the future.' UFC matchmakers were set to meet this week to shape what White said would be a loaded debut Paramount card. The UFC boss noted it was still too early to discuss a potential main event for the White House fight night. 'This is a 1-of-1 event,' White said. There are still some moving parts to UFC broadcasts and other television programming it has its hands in as the company moves into the Paramount era. White said there are still moving parts to the deal and that includes potentially finding new homes for 'The Ultimate Fighter,' 'Road To UFC,' and 'Dana White's Contender Series.' It's not necessarily a given the traditional 10 p.m. start time for what were the pay-per-view events would stand, especially on nights cards will also air on CBS. 'We haven't figured that out yet but we will,' White said. And what about the sometimes-contentious issue of fighter pay? Some established fighters have clauses in their contracts that they earn more money the higher the buyrate on their cards. Again, most of those issues are to-be-determined as UFC and Paramount settle in to the new deal — with $1.1 billion headed the fight company's way. 'It will affect fighter pay, big time,' White said. 'From deal-to-deal, fighter pay has grown, too. Every time we win, everybody wins.' Boxer Jake Paul wrote on social media the dying PPV model — which was overpriced for fights as UFC saw a decline in buys because of missing star power in many main events — should give the fighters an increased idea of their worth. 'Every fighter in the UFC now has a clear picture of what the revenue is…no more PPV excuses,' Paul wrote. 'Get your worth boys and girls.' White also scoffed at the idea that the traditional PPV model is dead. There are still UFC cards on pay-per-view the rest of the year through the end of the ESPN contract and White and Saudi Arabia have teamed to launch a new boxing venture that starts next year and could use a PPV home. White, though, is part of the promotional team for the Canelo Álvarez and Terence Crawford fight in September in Las Vegas that airs on Netflix. 'It's definitely not run it's course,' White said. 'There were guys out there who were interested in pay-per-view and there were guys out there that weren't. Wherever we ended up, that's what we're going to roll with.' White said UFC archival footage 'kills it' in repeat views and those classic bouts also needed a new home once the ESPN deal expires. Just when it seems there's little left for UFC to conquer, White says, there's always more. Why stop at becoming the biggest fight game in the world? Why not rewrite the pecking order in popularity and riches and go for No. 1 in all sports? 'You have the NFL, the NBA, the UFC, and soccer globally,' White said. 'We're coming. We're coming for all of them.'

I Shopped NYC's Biggest Flea Market for 7 Fashion Trends Locals Actually Wear—and You Can Get Them at Amazon
I Shopped NYC's Biggest Flea Market for 7 Fashion Trends Locals Actually Wear—and You Can Get Them at Amazon

Travel + Leisure

time16 minutes ago

  • Travel + Leisure

I Shopped NYC's Biggest Flea Market for 7 Fashion Trends Locals Actually Wear—and You Can Get Them at Amazon

If there's one thing I've learned since moving to New York City, it's that the most fashionable locals rarely wear mass-produced items. Instead, they often sport vintage, handmade, or one-of-a-kind pieces. That doesn't mean the city is immune to trends; New Yorkers instead just put their own spin on things, turning to flea markets and vintage shops to hunt for unique versions of trendy styles. I recently visited the Grand Bazaar, NYC's biggest flea market, which is flooded weekly with stylish locals. I took note of the seven most popular trends I spotted, and now, I'm sharing them with Travel + Leisure readers—along with affordable ways to shop the trends at Amazon. From vintage-inspired leather crossbody bags to celeb-approved track shorts, you can shop these top clothing styles from just $4. When wandering the Grand Bazaar, you can't help but notice that a few booths draw particularly large crowds. Many times, the most popular booths are the ones that sell vintage handbags and purses. I've found vintage-inspired crossbody bags at Amazon, along with sleek leather totes that remind me of the handmade ones I frequently spot at the market. My favorite thing about this style of bag is that they're truly timeless, so you can wear them in any season, for almost any occasion, and for years to come. Oversized button-downs are a wardrobe staple, and right now, pastel versions are taking over my social media feeds. When exploring New York's trendiest vintage markets, you'll find racks full of crisp shirts from Ralph Lauren, Tommy Hilfiger, and more—but similar styles at Amazon come with much better prices. I found shirts from $18, including butter yellow, blue striped, and other trendy versions. Throw them over a swimsuit, pair them with your favorite jeans, or dress them up for the office. Silk scarves are the international accessories of chic dressers, and my local flea market is overflowing with vintage options. While a pre-loved designer version could cost you upwards of $400, Amazon is full of affordable alternatives that channel the same elegance. Prices start at just $6. I've spotted dresses at Amazon that are just as unique as the vintage versions that fill New York's marketplaces. From tropical-printed dresses that are perfect for vacation to halter-neck mini versions you can wear on a girls' night out, these pieces will inject a dose of creative personal style into your wardrobe. I believe that jewelry is the hallmark of a truly stylish individual. Your jewelry can be a true reflection of you, so I love to shop unique statement jewelry at the Grand Bazaar. The flea market is full of gemstones, fidget rings, pendant necklaces, and other rare pieces. But you don't have to travel to the Upper West Side to snag similar items. I found beautiful statement jewelry at Amazon, including trending styles like a cord necklace and a resin bracelet. Bohemian blouses are back in a major way, but you don't need to splurge on vintage finds to get the style. Amazon options are more affordable and just as stylish, and they'll be in much better condition than secondhand versions (which tend to show more wear due to their delicate fabrics). From the crisp, structured Sweatyrocks Embroidered Blouse to the flowy Yiulangde Tie-front Lace Top, these tops ooze with New York panache—and no one will guess these romantic blouses are from Amazon. The shorts you wore as an awkward middle schooler have been co-opted by fashion lovers, and they're in high demand at secondhand markets. Track shorts are so trendy that even celebrities like Zoe Kravitz and Hailey Bieber have worn them, pairing them with open-toe heels and turning them into nighttime-worthy ensembles. Whether you're planning on wearing them casually or dressing them up, track shorts should be on your shopping list. Skip sifting through countless thrift racks when you can score them on Amazon for as low as $15. I particularly love the checkerboard-printed Umbro track shorts, which are marked down to just $28. Love a great deal? Sign up for our T+L Recommends newsletter and we'll send you our favorite travel products each week.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store